Abbildung 10: Telmisartan - LVH
This clinical study assessed the effect of 12 months’ treatment with telmisartan 40–80 mg on left ventricular mass index (LVMI) in 90 patients with hypertension and echocardiographic evidence of mild-to-moderate LVH.1 Mean SBP was reduced from 167 mmHg at baseline to 126 mmHg at treatment end (p<0.001) and mean DBP from 104 mmHg to 86 mmHg (p<0.001). There was a concomitant decrease in LVMI, from 121 ± 7 g/m2 at baseline to 109 ± 3 g/m2 at treatment end (p<0.01). Mattioli AV, et al. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004;97:383–388.